Lyell Immunopharma

Lyell Immunopharma

LYEL· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +140.5% in FY2025

Lynn Seely, M.D. is the CEO of Lyell Immunopharma and was paid $4.2M in FY2025 (Dec), up 182%.

Pay$100 in the stock at the end of FY21 → $20
CEO pay is from each Lyell Immunopharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Lynn Seely, M.D.FY2025
  2. 2Stephen HillFY2025
  3. 3Gary Lee, Ph.D.FY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Lyell Immunopharma paid its 3 named executives $8.2M in total in FY2025 (Dec). CEO Lynn Seely, M.D. was paid $4.2M of that.

Name
Lynn Seely, M.D.President, Chief Executive Officer and Director
Stephen HillChief Operating Officer
Gary Lee, Ph.D.Chief Scientific Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers21

See all

The FY2023 (Dec) proxy of Lyell Immunopharma names 21 peer companies for pay. Among Lyell Immunopharma and these peers, CEO pay was 10th highest of 12 and total shareholder return was 11th highest of 12.

10th highest of 12in Lyell Immunopharma and its pay peers, FY2023 (Dec) by CEO pay:

$1.2M$19.8M

11th highest of 12in Lyell Immunopharma and its pay peers, FY2023 (Dec) by total shareholder return:

$4$208

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board3

See all
  • Rick KlausnerChair · 6 yr on the boardIndependent—Paid as an executive
  • William RieflinDirector · 4 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive
  • Otis Brawley, M.D.Director · 3 yr on the boardIndependentNominating and Corporate Governance (Chair)—Paid as an executive

The board of the latest proxy (FY2024).

Activity

  1. Pay
    Lyell Immunopharma COO pay rose 55% to $2.1M. The stock rose 140% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Lyell Immunopharma CEO pay rose 182% to $4.2M. The stock rose 140% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Lyell Immunopharma Chief Scientific Officer pay rose 48% to $1.9M. The stock rose 140% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Lyell Immunopharma Chief Scientific Officer pay fell 41% to $1.3M. The stock fell 67% in FY2024 (Dec).
    DEF 14A
  5. Pay
    Lyell Immunopharma COO pay fell 57% to $1.3M. The stock fell 67% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Lyell Immunopharma Division head pay fell 53% to $1.9M. The stock fell 67% in FY2024 (Dec).
    DEF 14A
  7. Pay
    Lyell Immunopharma CEO pay fell 44% to $1.5M. The stock fell 67% in FY2024 (Dec).
    DEF 14A
  8. Pay
    Lyell Immunopharma COO pay fell 24% to $3.1M. The stock fell 44% in FY2023 (Dec).
    DEF 14A
  9. Pay
    Lyell Immunopharma COO pay rose 71% to $4.1M. The stock fell 55% in FY2022 (Dec).
    DEF 14A
  10. Pay
    Lyell Immunopharma CEO pay fell 86% to $2.6M. The stock fell 44% in FY2023 (Dec).
    DEF 14A
  11. Pay
    Lyell Immunopharma Chief Scientific Officer pay fell 46% to $2.2M. The stock fell 44% in FY2023 (Dec).
    DEF 14A
  12. Pay
    Lyell Immunopharma CFO pay rose 11% to $4.3M. The stock fell 44% in FY2023 (Dec).
    DEF 14A
  13. Pay
    Lyell Immunopharma CFO pay fell 80% to $3.9M. The stock fell 55% in FY2022 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 24, 2026FY2025
Annual report10-KMar 12, 2026FY2025
Proxy statementDEF 14AApr 21, 2025FY2024
Annual report10-KMar 11, 2025FY2024
Proxy statementDEF 14AApr 22, 2024FY2023
Annual report10-KFeb 28, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data